BioSpace News Archive

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 third quarter on Tuesday, November 8, 2022, after the market close.

4D Molecular Therapeutics, Inc. announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 will be presented during a symposium at the upcoming North American Cystic Fibrosis Conference, being held November 3-5, 2022.

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2022.

ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX) today announced the presentation of preclinical data for its lead first generation androgen receptor (“AR”) ANITen bAsed Chimera (“ANITAC"™) N-terminal domain (“NTD”) degrader in a poster session at the 34th EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2022.

KORU Medical Systems, a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, announced that the Company will report third quarter 2022 financial results on Wednesday, November 9, 2022.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022, after the close of the U.S. financial markets.

CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2022.

Bayer Inc. announced today that Health Canada approved finerenone, under the brand name KERENDIA®, as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of end-stage kidney disease and a sustained decrease in estimated glomerular filtration rate, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that it will release its financial results for the quarter ended September 30, 2022 after the market close on Wednesday, November 9 and will also host a conference call and webcast at 4:30 pm Eastern Standard Time on November 9, 2022.